<DOC>
	<DOCNO>NCT00759902</DOCNO>
	<brief_summary>The objective single-dose , open-label , randomize , two-treatment , two-period crossover study compare relative bioavailability test formulation KADIAN ( 2 x 10 mg ) capsule manufacture Alpharma Inc. equivalent oral dose commercially available reference product , KADIAN ( 1 x 20 mg ) capsule manufacture Alpharma Branded Products Inc. follow overnight fast least 10 hour .</brief_summary>
	<brief_title>Comparison Two KADIAN 10 mg Capsules KADIAN 20 mg Capsule Under Fasted Conditions</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<criteria>Subject must male nonpregnant , nonbreastfeeding female . Subject must 18 55 year age ( inclusive ) . Subject 's Body Mass Index ( BMI ) must 18 30 kg/m2 ( inclusive ) , subject must weigh minimum 50 kg ( 110 lb ) . Female subject surgically sterile least two year postmenopausal must agree utilize one follow form contraception , sexually active male partner , least screen completion study . Approved forms contraception abstinence , hormonal ( oral , implant , transdermal injection ) use least 3 consecutive month prior first dose study medication , double barrier ( condom diaphragm spermicide ) , intrauterine device ( IUD ) , vasectomized partner ( 6 month minimum since vasectomy ) . Subject must voluntarily consent participate study provide write informed consent prior completion studyspecific procedure . Subject willing able remain study unit entire duration confinement period return study site outpatient visit . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic psychiatric disease condition , opinion Investigator would jeopardize safety subject validity study result . Has clinically significant abnormal find physical exam , medical history , ECG clinical laboratory result screen . History presence allergic adverse response KADIAN relate drug . Has significantly abnormal diet four week precede first dose study medication . Has donate blood plasma within 30 day prior first dose study medication . Has participate another clinical trial within 30 day prior first dose study medication . Has use overthecounter ( OTC ) medication include nutritional supplement , within 7 day prior first dose study medication . Has use prescription medication , except hormonal contraceptive hormonal replacement therapy , within 14 day prior first dose study medication . Has treat know enzyme alter drug barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication . Has smoke use tobacco product within 60 day prior first dose study medication . Has history treatment substance abuse ( include alcohol ) past 5 year . Is female positive pregnancy test result . Has positive urine screen drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , cannabinoids , opiate ) . Has positive test , treat Hepatitis B , Hepatitis C HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>10 mg</keyword>
	<keyword>KADIAN capsule</keyword>
	<keyword>20 mg</keyword>
	<keyword>fast condition</keyword>
</DOC>